Detalhe da pesquisa
1.
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Blood
; 139(5): 732-747, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653238
2.
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Hematol Oncol
; 42(1): e3241, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38058031
3.
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Blood
; 138(3): 213-220, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292324
4.
Decision-Making among Experts in Advanced Hodgkin Lymphoma.
Oncology
; 101(3): 159-165, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103806
5.
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
BMC Cancer
; 22(1): 672, 2022 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717166
6.
Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
Hematol Oncol
; 40(4): 716-723, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35574642
7.
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Blood
; 134(4): 353-362, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101627
8.
Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland.
Eur J Cancer Care (Engl)
; 29(2): e13206, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31965647
9.
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Lancet
; 390(10114): 2790-2802, 2017 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061295
10.
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
Blood
; 127(18): 2189-92, 2016 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26834240
11.
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
Hematol Oncol
; 36(1): 84-92, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28621491
12.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Br J Haematol
; 176(5): 770-782, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27983764
13.
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
Support Care Cancer
; 25(9): 2833-2842, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28405846
14.
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
Lancet Oncol
; 17(10): 1453-1462, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27612583
15.
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Br J Haematol
; 174(2): 255-63, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27018242
16.
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Lancet
; 385(9976): 1418-27, 2015 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25539730
17.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Haematologica
; 101(3): 346-55, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659919
18.
Improved survival of older patients with multiple myeloma in the era of novel agents.
Hematol Oncol
; 34(4): 217-223, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25898820
19.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Blood
; 132(19): 2097-2100, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30237154
20.
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment.
Ann Hematol
; 94(11): 1839-43, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26246466